Find actively recruiting GLP-1 receptor agonist clinical trials in the UK. From semaglutide (Wegovy/Ozempic) to dual agonists, discover next-generation treatments for obesity, diabetes, and emerging indications.
Free to use — Live data from ClinicalTrials.gov — Updated hourly
GLP-1 receptor agonists mimic the action of glucagon-like peptide-1, a hormone that regulates blood sugar, appetite, and metabolism. Originally developed for type 2 diabetes, they have revolutionised obesity treatment and are now being studied for heart failure, kidney disease, liver disease, and even neurological conditions.
GLP-1 agonists work through multiple mechanisms: increasing insulin secretion in response to meals, reducing glucagon output, slowing gastric emptying, and acting on brain receptors to reduce appetite and increase satiety. Dual agonists (tirzepatide/Mounjaro) also target GIP receptors for even greater metabolic effect. Next-generation triple agonists targeting GLP-1, GIP, and glucagon are in development.
Actively recruiting studies in the United Kingdom
Loading trials from ClinicalTrials.gov...
Ozempic (semaglutide) and Mounjaro (tirzepatide) are approved for type 2 diabetes. Wegovy is the higher-dose version of semaglutide approved for weight management. Mounjaro's weight management version is Zepbound (tirzepatide). The key difference is that tirzepatide is a dual GLP-1/GIP agonist, while semaglutide targets GLP-1 only.
Yes — this is one of the most active areas of clinical research. Trials are investigating GLP-1 agonists for heart failure (SHOW results are very promising), chronic kidney disease, NASH/MASLD, Alzheimer's disease, Parkinson's disease, sleep apnoea, and addiction. The metabolic and anti-inflammatory effects appear to have broad therapeutic potential.
Yes. Many trials are recruiting for GLP-1 agonists across various conditions. Some provide access to newer dual or triple agonists not yet approved, or test GLP-1 agonists in new indications (e.g., heart failure without diabetes). Check our trial listings or use the Smart Matcher to find trials you may be eligible for.
GLP-1 Agonists is used across multiple conditions. Select your condition for targeted results.
How does this treatment compare with alternatives?